Skye Bioscience Inc SKYE
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-02-24 |
| Shares Out. | 35,140,000 |
| Website | skyebioscience.com/ ↗ |
| Phone | 18584100266 |
| Employees | 12 |
| Net Income | -$12.5M |
| Free Cash Flow | -$42.4M |
| Total Assets | $19.4M |
| Total Liabilities | $10.4M |
| Equity | $9.0M |
About Skye Bioscience Inc
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Skye Bioscience Inc is a publicly traded company under the ticker symbol SKYE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)